Most People Don’t Get Enough of Key Nutrients Linked to Alzheimer’s Risk

A new review finds 76% of the global population fail to meet recommended intakes of long-chain omega‑3s (EPA+DHA), with guidelines at 250 mg/day for adults and an extra 100–200 mg DHA advised in pregnancy; researchers and clinicians emphasize omega‑3s’ links to cardiovascular, cognitive and developmental health. Experts say dietary attainment is constrained by cost‑of‑living pressures, limited fish availability and cultural habits, making oily fish consumption (mackerel, salmon, sardines) or supplements the practical routes to adequacy. Clinicians interviewed recommend supplements that supply at least 500 mg combined EPA/DHA, with algae‑derived products for vegetarians, a dynamic that points to sustained demand for purified omega‑3 supplements and alternative sources amid supply and affordability challenges.

Analysis

A new global review and expert commentary reported that 76% of people worldwide fail to meet recommended intakes of long‑chain omega‑3s (combined EPA+DHA), with adult guidance at 250 mg/day and an extra 100–200 mg DHA advised in pregnancy (Calder et al., 2025). Clinicians in the article link adequate EPA/DHA intake to cardiovascular health, cognitive development and lower Alzheimer’s risk, framing the shortfall as clinically meaningful.

Experts identify cost‑of‑living pressures, reduced oily fish availability in certain regions and cultural dietary patterns as primary barriers to achieving intakes, noting that ALA conversion to EPA/DHA is insufficient to bridge the gap. Practical responses highlighted include eating oily fish once or twice weekly (mackerel, salmon, sardines) or using supplements; clinicians recommended supplements that provide at least 500 mg combined EPA/DHA, are purity/oxidation tested, and use triglyceride forms, with algae‑derived products for vegetarians.

The article implies sustained demand for high‑quality omega‑3 supplements and alternative sources amid supply and affordability constraints, a modestly positive market signal (impact score 0.12) and relevance to Healthcare & Biotech and Consumer Demand & Retail themes. Investors should expect greater focus on product quality certification, supply‑chain resilience (including algae sources) and regional demand divergence driven by price and fish availability.

Key Decisions for Investors

• Consider increasing exposure to reputable omega‑3 supplement manufacturers and algae‑derived omega‑3 producers that emphasize third‑party purity testing and triglyceride formulations, as expert guidance in the article favors these attributes
• Monitor seafood supply and pricing trends closely since reduced fish availability and cost‑of‑living pressures cited in the article could shift consumption toward supplements and non‑fish sources, benefiting firms with secure raw‑material supply
• Prioritize companies with demonstrable quality controls, third‑party testing and clinical credibility because the article highlights purity/oxidation testing as a differentiator that could drive consumer and prescriber preference
• Track scientific guidance and pregnancy‑related recommendations (additional DHA) as potential demand catalysts and be prepared to reassess positions if subsequent evidence or regulatory guidance changes the clinical narrative